Clinical trials: Atherothrombosis
Acute Coronary Syndrome
A Retrospective Swedish Cohort Study on Health Outcomes, Life Expectancy, Resource Use and Costs in Patients With a History of Myocardial Infarction and Additional Risk Factors for Atherothrombosis
To characterize and estimate the size of different populations with a history of acute coronary syndrome in Sweden. To assess the burden of illness (co-morbidities, mortality rates healthcare resource utilization and…
- Trial name
- HELICON (NCT01984307)
- Where
- Sweden
- Volunteers
- 100,000 people
- Sponsor
- AstraZeneca
Peripheral Arterial Disease, Carotid Stenosis
EValuation of Systemic Atherothrombosis in Patients With ARTerial Disease of the Lower Limbs
The purpose of this study is to determine the prevalence and risk factors, at the time of the diagnosis of PAD, for asymptomatic carotid stenosis and abdominal aortic aneurysm.
- Conditions
- Peripheral Arterial Disease, Carotid Stenosis, Abdominal Aortic Aneurysm
- Trial name
- EVART (NCT01224600)
- Testing
- patients with newly diagnosed PAD (<1year)
- Where
- 115 sites in Belgium, France
- Volunteers
- 1,056 people
- Sponsor
- Institut de l'Atherothrombose
Myocardial Infarction, Cardiovascular Death
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Trial name
- PEGASUS (NCT01225562)
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- 826 sites in United States, Argentina and 29 more
- Volunteers
- 21,379 people
- Sponsor
- AstraZeneca
Diabetes, Atherothrombosis
Atherothrombosis Markers in Diabetics
Intraplaque hemorrhage is the driving force of atherothrombotic plaque vulnerability to rupture and associated clinical complications.
- Conditions
- Diabetes, Atherothrombosis, Cardiovascular Disease
- Trial name
- MADI (NCT02898467)
- Testing
- diabetics, non-diabetics
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Air Pollution, Atherosclerosis
Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History
This double-blind, randomized, crossover trial aims to test the hypothesis that longer-term indoor air filtration intervention can slow atherothrombosis progression by reducing indoor fine particulate matter (PM2.5) exposure in…
- Trial name
- SAPIA (NCT05867381)
- Testing
- HEPA filtration
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- University of Southern California
Atherothrombosis
ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)
Investigation of the efficacy and safety of triflusal in comparison with aspirin in patients with stable coronary artery disease (CAD) and in those with a history of an acute non-cardioembolic ischemic stroke.
- Trial name
- ASTERIAS (NCT02616497)
- Testing
- Aspirin, Triflusal
- Where
- Greece
- Volunteers
- 1,220 people
- Sponsor
- University of Ioannina
HIV Infections
Coronary Artery Disease (CAD) in Patients HIV-infected
HIV-infected patients with intermediate-high risk have a high prevalence of CAD and a substantial proportion of obstructive CAD.
- Trial name
- CoroVIH (NCT04579146)
- Testing
- coronary computed tomographic angiographic (CCTA)
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Hôpital Européen Marseille
Diabetes Type 2, Hypertriglyceridemia
Study of the Efficacy and Safety of EPA in Patients With Type-2 Diabetes
Investigation of the efficacy and safety of an Eicosapentaenoic acid (EPA) supplement versus a placebo supplement on plasma triglyceride levels as well as inflammatory, thrombotic, endothelial and platelet activation markers, in…
- Conditions
- Diabetes Type 2, Hypertriglyceridemia, Diabetes Mellitus
- Trial name
- SEASIDE (NCT06129526)
- Testing
- EPAVasc, Corn Oil
- Where
- Greece
- Volunteers
- 450 people
- Sponsor
- University of Ioannina
Prevention of Subclinical Atherosclerosis Progression, Prevention of Cognitive Decline
Nattokinase Atherothrombotic Prevention Study
The potential for nattokinase to "thin" blood and to reduce blood clotting by positive antithrombotic and fibrinolytic effects presents a unique opportunity to safely study such effects on cardiovascular disease and cognition.
- Trial name
- NAPS (NCT02080520)
- Testing
- Nattokinase
- Where
- United States
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Coenzyme Q10 on Athero-thrombosis in APS Patients
Beneficial Effects of Coenzyme Q10 Treatment on the Mitochondrial Dysfunction and Oxidative Stress Associated to Atherothrombosis Developement in Antiphospholipidid Syndrome Patients
The study will be performed on 50 APS (antiphospholipid Syndrome) patients, which will be randomized to receive either CoQ10 (200mg/day) or placebo for one month. Blood will be drawn at time 0 and at the end of the treatment.
- Trial name
- coenzyme Q10 (NCT02218476)
- Testing
- CoQ10
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Vascular Function, Atherothrombosis
Effect of Fire Suppression and Emergency Duties on Vascular Function
Firefighters are at increased risk of death from heart attacks when compared to other emergencyy service professionals whose jobs involve similar components such as emergency call-outs and shift work.
- Trial name
- NCT01805063
- Testing
- Forearm Vascular Study, Badimon Chamber
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Coronary Artery Disease, Peripheral Arterial Disease
NEtwork to Control ATherothrombosis (NEAT Registry)
NEAT is an observational cohort (Prospective registry of real world data) of patients with coronary and peripheral artery disease in an outopatient setting.
- Conditions
- Coronary Artery Disease, Peripheral Arterial Disease, Atherothrombosis
- Trial name
- NEAT (NCT04677725)
- Where
- Brazil
- Volunteers
- 2,000 people
- Sponsor
- Hospital do Coracao
Cardiac and Hemodynamic Response, Blood Flow Distribution and Oxygen Uptake Efficiency
Effects of Aerobic Interval and Continuous Exercise Trainings in Patients With Chronic Heart Failure
Heart failure (HF) is a major and increasingly common cardiovascular syndrome, and is the end result of many cardiovascular disorders.
- Conditions
- Cardiac and Hemodynamic Response, Blood Flow Distribution and Oxygen Uptake Efficiency, Hemorheology Modulated by Erythrocyte, Atherothrombosis Modulated by Monocyte
- Trial name
- NCT01229670
- Testing
- exercise
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- Chang Gung Memorial Hospital
Vascular Function, Atherothrombosis
Effect of Real-fire Training on Vascular Function
Fire-fighters are at increased risk of death from heart attacks when compared to other emergency service professionals whose jobs involve similar components such as emergency call-outs and shift work.
- Trial name
- FIREPROOF (NCT01812317)
- Testing
- Forearm Vascular Study, Badimon Chamber Study
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Atherothrombosis, Type 2 Diabetes
Aspirin Resistance and Sleep Apnea in Type-2 Diabetic Patients
Type-2 Diabetes and Sleep Apnea Syndrome (SAS) are both related to an increase in platelet activation. Type 2 diabetes is often associated with sleep apnea syndrome with a prevalence up to 60%.
- Conditions
- Atherothrombosis, Type 2 Diabetes, Obstructive Sleep Apnea Syndrome
- Trial name
- AREAS (NCT01788930)
- Testing
- CPAP
- Where
- France
- Volunteers
- 53 people
- Sponsor
- University Hospital, Grenoble
Atherothrombosis
Pharmacogenomics of Antiplatelet Response - II (PARes-II)
This clinical trial is examining the effect of 4-week aspirin therapy on platelet transcriptome in persons at high-risk for myocardial infarction or stroke due to family history of early-onset coronary artery disease.
- Trial name
- PARes-II (NCT01894555)
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Johns Hopkins University
Ischemic Stroke, Atrial Fibrillation
Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis
The Purpose of this open-label randomized controlled multicenter trial is to evaluate the efficacy and safety of mono-drug therapy with oral anticoagulant compared to combination therapy with antiplatelet drug, in ischemic stroke…
- Conditions
- Ischemic Stroke, Atrial Fibrillation, Atherothrombosis
- Trial name
- ATIS-NVAF (NCT03062319)
- Testing
- Oral Anticoagulant, Antiplatelet Drug
- Where
- Japan
- Volunteers
- 321 people
- Sponsor
- National Hospital Organization Osaka National Hospital
Atherosclerosis
Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid
In this study researchers want to gain more information on treatment patterns of patients treated with Xarelto in combination with acetylsalicylic acid (ASA). Both drugs reduce the risk of blood clots via different pathways.
- Trial name
- XATOA (NCT03746275)
- Testing
- Rivaroxaban (BAY59-7939, Xarelto), Acetylsalicylic acid
- Where
- 18 sites in Argentina, Brazil and 16 more
- Volunteers
- 5,798 people
- Sponsor
- Bayer
Coronary Artery Disease
Active Detection of the Extension of Atherothrombosis in High Risk Coronary Patients
Coronary artery disease is the first cause of death related to atherothrombosis.
- Trial name
- AMERICA (NCT00445835)
- Testing
- Arterial doppler for screening asymptomatic and significant extracoronary arterial stenoses in all arterial beds, Conservative arm
- Where
- France
- Volunteers
- 526 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Heart Diseases, Ischemic
PET-MR Imaging of Coronary Atherothrombosis
Heart attacks remain a common cause of death throughout the world. The most common initiating event is the formation of a blood clot within the coronary arteries occluding blood supply to the heart.
- Trial name
- NCT03618303
- Testing
- PET-MRI scan
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- University of Edinburgh